The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling
Open accessAbstract
The RAAS through its physiological effectors plays a key role in promoting and maintaining inflammation. Inflammation is an important mechanism in the development and progression of CVD such as hypertension and atherosclerosis. In addition to its main role in regulating blood pressure and its role in hypertension, RAAS has proinflammatory and profibrotic effects at cellular and molecular levels. Blocking RAAS provides beneficial effects for the treatment of cardiovascular and renal diseases. Evidence shows that inhibition of RAAS positively influences vascular remodeling thus improving CVD outcomes. The beneficial vascular effects of RAAS inhibition are likely due to decreasing vascular inflammation, oxidative stress, endothelial dysfunction, and positive effects on regeneration of endothelial progenitor cells. Inflammatory factors such as ICAM-1, VCAM-1, TNFα, IL-6, and CRP have key roles in mediating vascular inflammation and blocking RAAS negatively modulates the levels of these inflammatory molecules. Some of these inflammatory markers are clinically associated with CVD events. More studies are required to establish long-term effects of RAAS inhibition on vascular inflammation, vascular cells regeneration, and CVD clinical outcomes. This review presents important information on RAAS’s role on vascular inflammation, vascular cells responses to RAAS, and inhibition of RAAS signaling in the context of vascular inflammation, vascular remodeling, and vascular inflammation-associated CVD. Nevertheless, the review also equates the need to rethink and rediscover new RAAS inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“available antagonists, eplerenone and spironolactone, have been shown to be effective treatment options for hypertension and heart failure [100].”
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Rajagopalan, S., Kurz, S., Münzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K., & Harrison, D. G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118623 · Cited by 2,449
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
STUDIES ON EXPERIMENTAL HYPERTENSION
Goldblatt, H., Lynch, J., Hanzal, R. F., & Summerville, W. W. (1934) · Journal of Experimental Medicine · doi:10.1084/jem.59.3.347 · Cited by 2,142
Jonjić, S., Mutter, W., Weiland, F., Reddehase, M. J., & Koszinowski, U. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.4.1199 · Cited by 2,105
Pathophysiology of coronary artery disease
Libby, P., & Theroux, P. (2005) · Circulation · doi:10.1161/circulationaha.105.537878 · Cited by 1,965
Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace
Förstermann, U., & Münzel, T. (2006) · Circulation · doi:10.1161/circulationaha.105.602532 · Cited by 1,957 · cited 3×
“Mechanistically, aliskiren and valsartan combination downregulates NADPH oxidase activity and therefore attenuates oxidative stress [59], which plays a key role in initiating the development of vascular inflammation and cardiovascular disease.”
InfluentialDirect Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.102.18.2165 · Cited by 1,940
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Cited by
Siti, H. N., Kamisah, Y., & Kamsiah, J. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.03.005 · Cited by 898
Free radicals and their impact on health and antioxidant defenses: a review
Chandimali, N., Bak, S. G., Park, E. H., Lim, H.-J., Won, Y.-S., Kim, E.-K., Park, S.-I., & Lee, S. J. (2025) · Cell Death Discovery · doi:10.1038/s41420-024-02278-8 · Cited by 669
How Western Diet And Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases
Kopp, W. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s216791 · Cited by 660
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
“This elegant system also plays a significant role in the promotion and maintenance of inflammation [18].”
Vascular smooth muscle cell in atherosclerosis
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2015) · Acta Physiologica · doi:10.1111/apha.12466 · Cited by 384
Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders
Upadhyay, R. K. (2015) · Journal of Lipids · doi:10.1155/2015/971453 · Cited by 360
García-Sánchez, A., Miranda-Díaz, A. G., & Cardona-Muñoz, E. G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2082145 · Cited by 331
Oxidative Stress, Inflammation, and Disease
Chatterjee, S. (2016) · Oxidative Stress and Biomaterials · doi:10.1016/b978-0-12-803269-5.00002-4 · Cited by 314
Inflammation, oxidative stress and renin angiotensin system in atherosclerosis
Husain, K. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.209 · Cited by 305
Muñoz-Durango, N., Fuentes, C., Castillo, A., González-Gómez, L., Vecchiola, A., Fardella, C., & Kalergis, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17070797 · Cited by 282
Senescent cells: a therapeutic target for cardiovascular disease
Childs, B. G., Li, H., & van Deursen, J. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95146 · Cited by 192
“org Volume 128 Number 4 April 2018 cardiovascular inflammation (149), investigating the link between senescence and the RAAS is a high priority.”
BackgroundRenin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD
Poznyak, A. V., Bharadwaj, D., Prasad, G., Grechko, A. V., Sazonova, M. A., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136702 · Cited by 142
“Angiotensin II acts as a direct inducer of endothelial dysfunction, which also triggers the alterations of smooth muscles previously initiated by classical cardiovascular risk factors [7].”
BackgroundInfluentialDeng, Z., Liu, Y., Wang, J., Wu, S., Geng, L., Sui, Z., & Zhang, Q. (2018) · Marine Drugs · doi:10.3390/md16090299 · Cited by 81
“Next, angiotensin I is hydrolyzed by ACE to angiotensin II, which then binds to angiotensin receptors and causes vasoconstriction [4].”
Metadata
- Authors
- Pacurari, M., Kafoury, R., Tchounwou, P. B., & Ndebele, K.
- Venue
- International Journal of Inflammation
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 2042-0099 (ISSN-L)
- 2090-8040
- OpenAlex
- W2051926037
- Cited by
- 374
- References
- 129
- FWCI
- 20.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.